Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Last trade$25.96
Day change-$0.45 (-1.70%)
Day range$25.56 – $26.90
Volume1,575,861
Market cap$13.20B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.2B
Price / earnings
—
Price / book
1.99×
Price / sales
2.56×
EV / sales
3.19×
EV / EBITDA
15.18×
Profitability
Earnings per share
-$0.29
Return on assets
-1.1%
Return on equity
-2.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.56×
Current ratio
1.78×
Quick ratio
0.91×
Cash ratio
0.22×
Cash flow
Price / cash flow
21.5×
Price / free cash flow
32.35×
Free cash flow
$408M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELAN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.27B
$1.37B
$1.37B
$1.14B
$1.14B
$1.24B
$1.19B
$1.02B
Cost of revenue
$545M
$570M
$586M
$555M
$530M
$528M
$509M
$501M
Gross profit
$720M
$798M
$785M
$589M
$607M
$713M
$684M
$519M
Selling, general and administrative
$393M
$449M
$381M
$338M
$351M
$400M
$341M
$300M
Research and development
$99M
$92M
$97M
$93M
$89M
$92M
$94M
$81M
Total operating expenses
$637M
$683M
$641M
$772M
$605M
$640M
$584M
$518M
Operating income
$83M
$115M
$144M
-$183M
$2M
$73M
$100M
$1M
Interest expense
-$59M
-$59M
-$57M
-$80M
-$52M
-$48M
-$40M
-$46M
Income before taxes
$24M
$56M
$87M
-$259M
-$50M
$25M
$60M
-$51M
Income taxes
$6M
$2M
$30M
$17M
-$16M
$14M
-$7M
-$43M
Net income
$18M
$54M
$57M
-$276M
-$34M
$11M
$67M
-$8M
Net income attributable to common shareholders
$18M
$54M
$57M
-$276M
-$34M
$11M
$67M
-$8M
EBITDA
$263M
$295M
$332M
$193M
$203M
$243M
$270M
$172M
Basic earnings per share
$0.04
$0.11
$0.11
-$0.56
-$0.07
$0.02
$0.14
-$0.02
Diluted earnings per share
$0.04
$0.11
$0.11
-$0.56
-$0.07
$0.02
$0.13
-$0.02
Recent news
Company coverage with links to the original publishers.
Elanco Animal Health reported Q3 2026 revenue growth of 11% year-over-year to $1.265 billion, driven by strong pricing power on proprietary products and innovation. The company reduced gross debt by $216 million, achieving sub-3.0x net leverage ahead of schedule, and is targeting $200-250 million in EBITDA savings through its Elanco Ascend efficiency program by 2030. Management maintains pricing discipline without aggressive discounting while expanding market share in high-value treatment categories.
Mexico's animal healthcare market is projected to grow from USD 2.13 billion in 2025 to USD 3.34 billion by 2031, with a CAGR of 7.84%. Growth is driven by rising companion animal spending, expanding livestock production, stronger biosecurity requirements, and innovation in veterinary diagnostics. Key challenges include high costs, limited rural infrastructure, and counterfeit medicines.
Elanco Animal Health reported Q3 2026 earnings of $0.27 per share, beating consensus estimates of $0.20, with a 35% earnings surprise. Revenues reached $1.27 billion, surpassing estimates by 4.91% compared to $1.14 billion year-ago. The company has beaten consensus estimates four consecutive quarters. However, the stock has underperformed the S&P 500 year-to-date, gaining 4.6% versus the market's 7.4%. Zacks assigned the stock a Rank #3 (Hold) rating with mixed estimate revisions.
U.S. Physical Therapy reported Q3 2026 earnings of $0.80 per share, beating consensus estimates of $0.76, with revenues of $222.56 million exceeding expectations by 3.56%. However, the company has only surpassed EPS estimates once in the last four quarters. Assigned a Zacks Rank #3 (Hold), the stock is expected to perform in line with the market. The company has underperformed the S&P 500 year-to-date with an 8.5% gain versus the index's 10.6%.
RadNet (RDNT) is expected to report Q3 2026 earnings of $0.21 per share with 21.9% revenue growth, but analysts have recently become bearish with an Earnings ESP of -18.07%, making an earnings beat unlikely despite the company's strong historical surprise record of +38.10% in the last quarter.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.